4//SEC Filing
BAYER AKTIENGESELLSCHAFT 4
Accession 0001578563-21-000038
CIK 0001782223other
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 5:05 PM ET
Size
11.6 KB
Accession
0001578563-21-000038
Insider Transaction Report
Form 4
Bayer World Investments B.V.
10% Owner
Transactions
- Conversion
Common Stock
2021-10-13+2,742,338→ 2,742,338 total - Conversion
Series A Convertible Preferred Stock
2021-10-13−11,362,462→ 0 total→ Common Stock (1,786,831 underlying) - Conversion
Series B Convertible Preferred Stock
2021-10-13−6,076,072→ 0 total→ Common Stock (955,507 underlying)
Footnotes (2)
- [F1]Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.
- [F2]The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
Documents
Issuer
Pyxis Oncology, Inc.
CIK 0001782223
Entity typeother
Related Parties
1- filerCIK 0001144145
Filing Metadata
- Form type
- 4
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 5:05 PM ET
- Size
- 11.6 KB